Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jan 31;13(1):22-24.
doi: 10.21037/tcr-23-1763. Epub 2024 Jan 17.

Immune checkpoint inhibitors in combination with chemotherapy for patients with biliary tract cancer: what did we learn from TOPAZ-1 and KEYNOTE-966

Khaldoun Almhanna  1
Affiliations
Editorial

Immune checkpoint inhibitors in combination with chemotherapy for patients with biliary tract cancer: what did we learn from TOPAZ-1 and KEYNOTE-966

Khaldoun Almhanna. Transl Cancer Res. .
No abstract available

Keywords: Biliary cancer; KEYNOTE-966; TOPAZ-1.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-1763/coif). K.A. reports he received payment from AstraZeneca for a training session as a speaker. The author has no other conflicts of interest to declare.

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin 2023;73:17-48. 10.3322/caac.21763 - DOI - PubMed
    1. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-81. 10.1056/NEJMoa0908721 - DOI - PubMed
    1. Rimini M, Fornaro L, Lonardi S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data. Liver Int 2023;43:1803-12. 10.1111/liv.15641 - DOI - PubMed
    1. Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;401:1853-65. Erratum in: Lancet 2023;402:964. 10.1016/S0140-6736(23)00727-4 - DOI - PubMed
    1. Yoo C, Finn RS, Klümpen HJ, et al. Health-related quality of life (HRQoL) in the phase 3 KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) versus placebo plus gem/cis for advanced biliary tract cancer (BTC). J Clin Oncol 2023;41:4003. 10.1200/JCO.2023.41.16_suppl.4003 - DOI